{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:00:28Z","timestamp":1793746828066,"version":"4.6.1"},"publisher-location":"Cham","reference-count":115,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031051173","type":"print"},{"value":"9783031051180","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/164_2021_545","type":"book-chapter","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T09:49:48Z","timestamp":1642153788000},"page":"245-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders"],"prefix":"10.1007","author":[{"given":"Kaitlyn Koenig","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella E.","family":"Tsirka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"issue":"9","key":"545_CR1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/nn.2887","volume":"14","author":"B Ajami","year":"2011","unstructured":"Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM (2011) Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 14(9):1142\u20131149. https:\/\/doi.org\/10.1038\/nn.2887","journal-title":"Nat Neurosci"},{"issue":"2","key":"545_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.it.2003.12.004","volume":"25","author":"CW Ang","year":"2004","unstructured":"Ang CW, Jacobs BC, Laman JD (2004) The Guillain-Barre syndrome: a true case of molecular mimicry. Trends Immunol 25(2):61\u201366. https:\/\/doi.org\/10.1016\/j.it.2003.12.004","journal-title":"Trends Immunol"},{"issue":"10044","key":"545_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/s0140-6736(16)30169-6","volume":"388","author":"HL Atkins","year":"2016","unstructured":"Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, Freedman MS (2016) Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 388(10044):576\u2013585. https:\/\/doi.org\/10.1016\/s0140-6736(16)30169-6","journal-title":"Lancet"},{"key":"545_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","volume":"30","author":"D Baker","year":"2019","unstructured":"Baker D, Pryce G, Herrod SS, Schmierer K (2019) Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord 30:176\u2013186. https:\/\/doi.org\/10.1016\/j.msard.2019.02.018","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"545_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s13311-017-0553-8","volume":"14","author":"LE Baldassari","year":"2017","unstructured":"Baldassari LE, Rose JW (2017) Daclizumab: development, clinical trials, and practical aspects of use in multiple sclerosis. Neurotherapeutics 14(4):842\u2013858. https:\/\/doi.org\/10.1007\/s13311-017-0553-8","journal-title":"Neurotherapeutics"},{"issue":"5","key":"545_CR6","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood-2004-07-2921","volume":"105","author":"S Beyth","year":"2005","unstructured":"Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105(5):2214\u20132219","journal-title":"Blood"},{"issue":"9","key":"545_CR7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","volume":"67","author":"DB Bichuetti","year":"2010","unstructured":"Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, de Souza NA, Gabbai AA (2010) Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 67(9):1131\u20131136","journal-title":"Arch Neurol"},{"issue":"15","key":"545_CR8","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1073\/pnas.0601335103","volume":"103","author":"B Bielekova","year":"2006","unstructured":"Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R (2006) Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Ra-targeted therapy (daclizumab) in multiple sclerosis. PNAS 103(15):5941\u20135946","journal-title":"PNAS"},{"key":"545_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2174\/157488812804484648","volume":"7","author":"MM Bonab","year":"2012","unstructured":"Bonab MM, Sahraian MA, Aghhsaie A, Karvigh SA, Hosseinian SM, Nikbin B, Lotfi J, Khorramnia S, Motamed MR, Togha M, Harirchian MH, Moghadam NB, Alikhani K, Yadegari S, Jafarian S, Gheini MR (2012) Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. Curr Stem Cell Res Ther 7:407\u2013414","journal-title":"Curr Stem Cell Res Ther"},{"issue":"3","key":"545_CR10","first-page":"575","volume":"137","author":"EA Boyle","year":"1990","unstructured":"Boyle EA, McGeer PL (1990) Cellular immune response in multiple sclerosis plaques. Am J Pathol 137(3):575\u2013584","journal-title":"Am J Pathol"},{"key":"545_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jns.2019.03.030","volume":"401","author":"M Boziki","year":"2019","unstructured":"Boziki M, Lagoudaki R, Melo P, Kanidou F, Bakirtzis C, Nikolaidis I, Grigoriadou E, Afrantou T, Tatsi T, Matsi S, Grigoriadis N (2019) Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate. J Neurol Sci 401:43\u201350. https:\/\/doi.org\/10.1016\/j.jns.2019.03.030","journal-title":"J Neurol Sci"},{"issue":"3","key":"545_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10072-008-0934-1","volume":"29","author":"M Capobianco","year":"2008","unstructured":"Capobianco M, Malucchi S, Ulisciani S, Fava C, Cambrin GR, Avonto L, Saglio G, Bertolotto A (2008) Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. Neurol Sci 29(3):185\u2013187. https:\/\/doi.org\/10.1007\/s10072-008-0934-1","journal-title":"Neurol Sci"},{"key":"545_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/WNL.56.1.94","volume":"56","author":"V Chaudhry","year":"2001","unstructured":"Chaudhry V, Cornblat DR, Griffin JW, O\u2019Brien R, Drachman DB (2001) Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56:94\u201396","journal-title":"Neurology"},{"key":"545_CR14","doi-asserted-by":"publisher","first-page":"CD001798","DOI":"10.1002\/14651858.CD001798.pub3","volume":"2","author":"S Chevret","year":"2017","unstructured":"Chevret S, Hughes RA, Annane D (2017) Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2:CD001798. https:\/\/doi.org\/10.1002\/14651858.CD001798.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"545_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0074-7742(07)79003-7","volume":"79","author":"T Chitnis","year":"2007","unstructured":"Chitnis T (2007) The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 79:43\u201372","journal-title":"Int Rev Neurobiol"},{"key":"545_CR16","doi-asserted-by":"publisher","first-page":"175628641987118","DOI":"10.1177\/1756286419871187","volume":"12","author":"K Choi","year":"2019","unstructured":"Choi K, Hong YH, Ahn SH, Baek SH, Kim JS, Shin JY, Sung JJ (2019) Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis. Ther Adv Neurol Disord 12:1756286419871187. https:\/\/doi.org\/10.1177\/1756286419871187","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"545_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.55.3.448","volume":"55","author":"E Ciafaloni","year":"2000","unstructured":"Ciafaloni E, Nirjaleshwar K, Nikhar K, Massey JM, Sanders DB (2000) Restrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 55(3):448\u2013450","journal-title":"Neurology"},{"issue":"1","key":"545_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clim.2011.02.011","volume":"142","author":"MC Claussen","year":"2012","unstructured":"Claussen MC, Korn T (2012) Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol 142(1):49\u201356. https:\/\/doi.org\/10.1016\/j.clim.2011.02.011","journal-title":"Clin Immunol"},{"issue":"5","key":"545_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402\u2013415","journal-title":"N Engl J Med"},{"issue":"9856","key":"545_CR20","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/s0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819\u20131828. https:\/\/doi.org\/10.1016\/s0140-6736(12)61769-3","journal-title":"Lancet"},{"issue":"9856","key":"545_CR21","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/s0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829\u20131839. https:\/\/doi.org\/10.1016\/s0140-6736(12)61768-1","journal-title":"Lancet"},{"key":"545_CR22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-","volume":"274","author":"G Comi","year":"2009","unstructured":"Comi G, Martinelli V, Rodegher M, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Raavnborg M, Young C, Filippi M (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 274:1503\u20131511. https:\/\/doi.org\/10.1016\/S0140-","journal-title":"Lancet"},{"key":"545_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, Rieckmann P, Sorensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F (2019) Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord 29:168\u2013174. https:\/\/doi.org\/10.1016\/j.msard.2019.01.038","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"545_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","volume":"107","author":"A Corcione","year":"2006","unstructured":"Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107(1):367\u2013372","journal-title":"Blood"},{"key":"545_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77:659\u2013666","journal-title":"Neurology"},{"issue":"7","key":"545_CR26","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BAC Cree","year":"2005","unstructured":"Cree BAC, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64(7):1270\u20131272","journal-title":"Neurology"},{"issue":"9","key":"545_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15(9):545\u2013558. https:\/\/doi.org\/10.1038\/nri3871","journal-title":"Nat Rev Immunol"},{"key":"545_CR28","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1212\/WNL.0b013e3181c97d99","volume":"74","author":"S Dhib-Jalbut","year":"2010","unstructured":"Dhib-Jalbut S, Marks S (2010) Interferon-beta mechanisms of action in multiple sclerosis. Neurology 74:S17\u2013S24","journal-title":"Neurology"},{"issue":"3","key":"545_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.exphem.2007.11.007","volume":"36","author":"M Di Ianni","year":"2008","unstructured":"Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, Sportoletti P, Falzetti F, Tabilio A (2008) Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 36(3):309\u2013318. https:\/\/doi.org\/10.1016\/j.exphem.2007.11.007","journal-title":"Exp Hematol"},{"issue":"1","key":"545_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","volume":"93","author":"R Dutta","year":"2011","unstructured":"Dutta R, Trapp BD (2011) Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 93(1):1\u201312. https:\/\/doi.org\/10.1016\/j.pneurobio.2010.09.005","journal-title":"Prog Neurobiol"},{"key":"545_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1468-1331.2004.00986.x","volume":"12","author":"E Ersoy","year":"2005","unstructured":"Ersoy E, Kus CNS, Sener U, Coker I, Zorlu Y (2005) The effects of interferong-beta on interleukin-10 in multiple sclerosis patients. Eur J Neurol 12:208\u2013211","journal-title":"Eur J Neurol"},{"key":"545_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jneuroim.2015.04.006","volume":"283","author":"GO Gillard","year":"2015","unstructured":"Gillard GO, Collette B, Anderson J, Chao J, Scannevin RH, Huss DJ, Fontenot JD (2015) DMF, but not other fumarates, inhibits NF-kappaB activity in vitro in an Nrf2-independent manner. J Neuroimmunol 283:74\u201385. https:\/\/doi.org\/10.1016\/j.jneuroim.2015.04.006","journal-title":"J Neuroimmunol"},{"key":"545_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","volume":"369","author":"L Gotterer","year":"2016","unstructured":"Gotterer L, Li Y (2016) Maintenance immunosuppression in myasthenia gravis. J Neurol Sci 369:294\u2013302. https:\/\/doi.org\/10.1016\/j.jns.2016.08.057","journal-title":"J Neurol Sci"},{"key":"545_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/ana","volume":"75","author":"R Greco","year":"2014","unstructured":"Greco R, Bondanza A, Vago L, Moiola L, Rossi P, Furlan R, Martino G, Radaelli M, Martinelli V, Carbone MR, Stanghellini MTL, Assanelli M, Bernardi M, Corti C, Peccatori J, Bonini C, Vezzulli P, Falini A, Ciceri F, Comi G (2014) Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Ann Neurol 75:447\u2013453. https:\/\/doi.org\/10.1002\/ana","journal-title":"Ann Neurol"},{"key":"545_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","volume":"15","author":"JA Gross","year":"2001","unstructured":"Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 15:289\u2013302","journal-title":"Immunity"},{"issue":"8","key":"545_CR36","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","volume":"35","author":"Group TG-BSS","year":"1985","unstructured":"Group TG-BSS (1985) Plasmaphresis and acute Guillain-Barre syndrome. Neurology 35(8):1096\u20131104","journal-title":"Neurology"},{"key":"545_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ebiom.2018.02.002","volume":"29","author":"VK Harris","year":"2018","unstructured":"Harris VK, Stark J, Vyshkina T, Blackshear L, Joo G, Stefanova V, Sara G, Sadiq SA (2018) Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine 29:23\u201330. https:\/\/doi.org\/10.1016\/j.ebiom.2018.02.002","journal-title":"EBioMedicine"},{"issue":"9350","key":"545_CR38","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/s0140-6736(02)12023-x","volume":"360","author":"H-P Hartung","year":"2002","unstructured":"Hartung H-P, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018\u20132025. https:\/\/doi.org\/10.1016\/s0140-6736(02)12023-x","journal-title":"Lancet"},{"key":"545_CR39","doi-asserted-by":"publisher","unstructured":"Hartung HP, Graf J, Kremer D (2019) Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. J Neurol. https:\/\/doi.org\/10.1007\/s00415-018-09169-w","DOI":"10.1007\/s00415-018-09169-w"},{"issue":"1","key":"545_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","volume":"52","author":"SL Hauser","year":"2006","unstructured":"Hauser SL, Oksenberg JR (2006) The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52(1):61\u201376. https:\/\/doi.org\/10.1016\/j.neuron.2006.09.011","journal-title":"Neuron"},{"key":"545_CR41","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1212\/WNL.51.3.912-a","volume":"51","author":"RA Hauser","year":"1998","unstructured":"Hauser RA, Malek AR, Rosen R (1998) Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 51:912\u2013913","journal-title":"Neurology"},{"issue":"4","key":"545_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrn784","volume":"3","author":"B Hemmer","year":"2002","unstructured":"Hemmer B, Archelos JJ, Hartung HP (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3(4):291\u2013301. https:\/\/doi.org\/10.1038\/nrn784","journal-title":"Nat Rev Neurosci"},{"key":"545_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/b978-0-12-800763-1.00015-4","volume-title":"Multiple sclerosis","author":"Z Hojati","year":"2016","unstructured":"Hojati Z, Kay M, Dehghanian F (2016) Mechanism of action of interferon beta in treatment of multiple sclerosis. In: Multiple sclerosis. Academic Press, pp 365\u2013392. https:\/\/doi.org\/10.1016\/b978-0-12-800763-1.00015-4"},{"issue":"12","key":"545_CR44","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O\u2019Brien F, Wang JJ, Mantegazza R (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986","journal-title":"Lancet Neurol"},{"issue":"9497","key":"545_CR45","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/s0140-6736(05)67665-9","volume":"366","author":"RAC Hughes","year":"2005","unstructured":"Hughes RAC, Cornblath DR (2005) Guillain-Barr\u00e9 syndrome. Lancet 366(9497):1653\u20131666. https:\/\/doi.org\/10.1016\/s0140-6736(05)67665-9","journal-title":"Lancet"},{"key":"545_CR46","doi-asserted-by":"publisher","first-page":"CD002063","DOI":"10.1002\/14651858.CD002063.pub6","volume":"9","author":"RA Hughes","year":"2014","unstructured":"Hughes RA, Swan AV, van Doorn PA (2014) Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 9:CD002063. https:\/\/doi.org\/10.1002\/14651858.CD002063.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"545_CR47","doi-asserted-by":"publisher","first-page":"CD001446","DOI":"10.1002\/14651858.CD001446.pub5","volume":"10","author":"RA Hughes","year":"2016","unstructured":"Hughes RA, Brassington R, Gunn AA, van Doorn PA (2016) Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev 10:CD001446. https:\/\/doi.org\/10.1002\/14651858.CD001446.pub5","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"545_CR48","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kaantarci OH, Pittock SJ (2009) Treatment of neuromyelitis optica with mycophenolate mofetil - retrospective analysis of 24 patients. Arch Neurol 66(9):1128\u20131133","journal-title":"Arch Neurol"},{"issue":"7","key":"545_CR49","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"K Johnson","year":"1995","unstructured":"Johnson K, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7):1268\u20131276","journal-title":"Neurology"},{"issue":"4","key":"545_CR50","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/s1474-4422(14)70028-6","volume":"13","author":"L Kappos","year":"2014","unstructured":"Kappos L, Hartung H-P, Freedman MS, Boyko A, Rad\u00fc EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J (2014) Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol 13(4):353\u2013363. https:\/\/doi.org\/10.1016\/s1474-4422(14)70028-6","journal-title":"Lancet Neurol"},{"key":"545_CR51","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood-2002-07-","volume":"101","author":"M Karampera","year":"2003","unstructured":"Karampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F (2003) Bone marrow mesencyhmal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101:3722\u20133729. https:\/\/doi.org\/10.1182\/blood-2002-07-","journal-title":"Blood"},{"issue":"6","key":"545_CR52","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s12026-018-9032-5","volume":"66","author":"D Karussis","year":"2018","unstructured":"Karussis D, Petrou P (2018) Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale. Immunol Res 66(6):642\u2013648. https:\/\/doi.org\/10.1007\/s12026-018-9032-5","journal-title":"Immunol Res"},{"key":"545_CR53","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.4049\/jimmunol.148.6.1693","volume":"148","author":"DM Karussis","year":"1992","unstructured":"Karussis DM, Slavin S, Lehmann D, Mizrachi-Koll R, Abramsky O, Ben-Nun A (1992) Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation? J Immunol 148:1693\u20131698","journal-title":"J Immunol"},{"issue":"2","key":"545_CR54","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1172\/JCI116648","volume":"92","author":"DM Karussis","year":"1993","unstructured":"Karussis DM, Vourka-Karussis U, Lehmann D, Ovadia H, Mizrachi-Koll R, Ben-Nun A, Abramsky O, Slavin S (1993) Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest 92(2):765\u2013772. https:\/\/doi.org\/10.1172\/JCI116648","journal-title":"J Clin Invest"},{"issue":"6","key":"545_CR55","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/archneur.65.6.753","volume":"65","author":"I Kassis","year":"2008","unstructured":"Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S, Abramsky O, Karussis D (2008) Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 65(6):753\u2013761","journal-title":"Arch Neurol"},{"issue":"11","key":"545_CR56","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011a) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68(11):1412\u20131420. https:\/\/doi.org\/10.1001\/archneurol.2011.154","journal-title":"Arch Neurol"},{"issue":"4","key":"545_CR57","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/archneurol.2010.322","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ (2011b) Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 68(4):473\u2013479. https:\/\/doi.org\/10.1001\/archneurol.2010.322","journal-title":"Arch Neurol"},{"issue":"9","key":"545_CR58","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70(9):1110\u20131117. https:\/\/doi.org\/10.1001\/jamaneurol.2013.3071","journal-title":"JAMA Neurol"},{"issue":"4","key":"545_CR59","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/jnnp-2018-318465","volume":"90","author":"SH Kim","year":"2019","unstructured":"Kim SH, Kim Y, Kim G, Park NY, Jang HM, Shin HJ, Hyun JW, Kim HJ (2019) Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment. J Neurol Neurosurg Psychiatry 90(4):486\u2013487. https:\/\/doi.org\/10.1136\/jnnp-2018-318465","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"545_CR60","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","volume":"13","author":"I Kleiter","year":"2016","unstructured":"Kleiter I, Gold R (2016) Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 13(1):70\u201383. https:\/\/doi.org\/10.1007\/s13311-015-0400-8","journal-title":"Neurotherapeutics"},{"issue":"2","key":"545_CR61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/archneurol.2011.216","volume":"69","author":"I Kleiter","year":"2012","unstructured":"Kleiter I, Hellwig K, Berthele A, Kumpfel T, Linker RA, Hartung H-P, Paul F, Aktas O (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69(2):239\u2013245","journal-title":"Arch Neurol"},{"issue":"6","key":"545_CR62","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","volume":"5","author":"I Kleiter","year":"2018","unstructured":"Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kumpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Nemos (2018) Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 5(6):e504. https:\/\/doi.org\/10.1212\/NXI.0000000000000504","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"47","key":"545_CR63","doi-asserted-by":"publisher","first-page":"18460","DOI":"10.1073\/pnas.0809850105","volume":"105","author":"T Korn","year":"2008","unstructured":"Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, Vollmar P, Stritesky GL, Kaplan MH, Waisman A, Kuchroo VK, Oukka M (2008) IL-6 controls Th17 immunity in vivo by inhibitin the conversion of conventional T cells into Foxp3+ regulatory T cells. PNAS 105(47):18460\u201318465","journal-title":"PNAS"},{"issue":"1","key":"545_CR64","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1523\/JNEUROSCI.2615-05.2006","volume":"26","author":"MR Kotter","year":"2006","unstructured":"Kotter MR, Li WW, Zhao C, Franklin RJ (2006) Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci 26(1):328\u2013332. https:\/\/doi.org\/10.1523\/JNEUROSCI.2615-05.2006","journal-title":"J Neurosci"},{"issue":"2","key":"545_CR65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.20041674","volume":"201","author":"M Krumbholz","year":"2005","unstructured":"Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, Kalled SL, Hess DM, Serafini B, Aloisi F, Wekerle H, Hohlfeld R, Meinl E (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201(2):195\u2013200. https:\/\/doi.org\/10.1084\/jem.20041674","journal-title":"J Exp Med"},{"issue":"9997","key":"545_CR66","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/s0140-6736(15)61137-0","volume":"386","author":"E Le Page","year":"2015","unstructured":"Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G (2015) Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 386(9997):974\u2013981. https:\/\/doi.org\/10.1016\/s0140-6736(15)61137-0","journal-title":"Lancet"},{"issue":"1","key":"545_CR67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","volume":"34","author":"TP Leist","year":"2011","unstructured":"Leist TP, Weissert R (2011) Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 34(1):28\u201335. https:\/\/doi.org\/10.1097\/WNF.0b013e318204cd90","journal-title":"Clin Neuropharmacol"},{"key":"545_CR68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","volume":"151","author":"C Liang","year":"2018","unstructured":"Liang C, Tian D, Ren X, Ding S, Jia M, Xin M, Thareja S (2018) The development of Bruton\u2019s tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review. Eur J Med Chem 151:315\u2013326. https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.062","journal-title":"Eur J Med Chem"},{"issue":"1","key":"545_CR69","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","volume":"53","author":"Q Ma","year":"2013","unstructured":"Ma Q (2013) Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53(1):401\u2013426. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011112-140320","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"545_CR70","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","volume":"51","author":"RN Mandler","year":"1998","unstructured":"Mandler RN, Ahmed W, Dencof JE (1998) Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51:1219\u20131220","journal-title":"Neurology"},{"issue":"3","key":"545_CR71","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71(3):324\u2013330. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5699","journal-title":"JAMA Neurol"},{"key":"545_CR72","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1352458511431973","volume":"18","author":"JH Min","year":"2012","unstructured":"Min JH, Kim BJ, Lee KH (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 18:113\u2013115","journal-title":"Mult Scler"},{"issue":"1\u20132","key":"545_CR73","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jns.2010.09.033","volume":"300","author":"N Minami","year":"2011","unstructured":"Minami N, Fujiki N, Doi S, Shima K, Niino M, Kikuchi S, Sasaki H (2011) Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci 300(1\u20132):59\u201362. https:\/\/doi.org\/10.1016\/j.jns.2010.09.033","journal-title":"J Neurol Sci"},{"issue":"2","key":"545_CR74","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1207\/S15324796ABM2302_7","volume":"23","author":"DC Mohr","year":"2001","unstructured":"Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE (2001) Injectible medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 23(2):125\u2013132","journal-title":"Ann Behav Med"},{"issue":"3","key":"545_CR75","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS, Investigators OC (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"issue":"25","key":"545_CR76","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","volume":"380","author":"X Montalban","year":"2019","unstructured":"Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS, Evobrutinib Phase 2 Study Group (2019) Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med 380(25):2406\u20132417. https:\/\/doi.org\/10.1056\/NEJMoa1901981","journal-title":"N Engl J Med"},{"issue":"1","key":"545_CR77","doi-asserted-by":"publisher","first-page":"8194","DOI":"10.1038\/s41598-018-26519-w","volume":"8","author":"G Montes Diaz","year":"2018","unstructured":"Montes Diaz G, Fraussen J, Van Wijmeersch B, Hupperts R, Somers V (2018) Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients. Sci Rep 8(1):8194. https:\/\/doi.org\/10.1038\/s41598-018-26519-w","journal-title":"Sci Rep"},{"key":"545_CR78","doi-asserted-by":"publisher","first-page":"175628641877302","DOI":"10.1177\/1756286418773025","volume":"11","author":"P Mulero","year":"2018","unstructured":"Mulero P, Midaglia L, Montalban X (2018) Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord 11:1756286418773025. https:\/\/doi.org\/10.1177\/1756286418773025","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"545_CR79","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","volume":"74","author":"PA Muraro","year":"2017","unstructured":"Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trneny M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R, Multiple Sclerosis-Autologous Hematopoietic Stem Cell Transplantation Long-term Outcomes Study Group (2017) Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol 74(4):459\u2013469. https:\/\/doi.org\/10.1001\/jamaneurol.2016.5867","journal-title":"JAMA Neurol"},{"issue":"8","key":"545_CR80","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2169\/internalmedicine.47.0513","volume":"47","author":"A Nagaishi","year":"2008","unstructured":"Nagaishi A, Yukitake M, Kuroda Y (2008) Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. Intern Med 47(8):731\u2013736. https:\/\/doi.org\/10.2169\/internalmedicine.47.0513","journal-title":"Intern Med"},{"key":"545_CR81","first-page":"1203","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreaux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS (2011) Randomized trial of oral teriflunomid for relapsing multiple sclerosis. N Engl J Med 365:1203\u20131303","journal-title":"N Engl J Med"},{"key":"545_CR82","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1212\/WNL.0000000000002441","volume":"86","author":"P O\u2019Connor","year":"2016","unstructured":"O\u2019Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard J-P, Lebrun-Frenay C, Mares J, Benamor J, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS (2016) Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology 86:920\u2013930","journal-title":"Neurology"},{"issue":"6","key":"545_CR83","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50(6):1778\u20131783","journal-title":"Neurology"},{"issue":"6","key":"545_CR84","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/s1474-4422(12)70133-3","volume":"11","author":"MC Papadopoulos","year":"2012","unstructured":"Papadopoulos MC, Verkman AS (2012) Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11(6):535\u2013544. https:\/\/doi.org\/10.1016\/s1474-4422(12)70133-3","journal-title":"Lancet Neurol"},{"issue":"4","key":"545_CR85","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.rdc.2017.06.007","volume":"43","author":"SL Patterson","year":"2017","unstructured":"Patterson SL, Goglin SE (2017) Neuromyelitis Optica. Rheum Dis Clin N Am 43(4):579\u2013591. https:\/\/doi.org\/10.1016\/j.rdc.2017.06.007","journal-title":"Rheum Dis Clin N Am"},{"issue":"4","key":"545_CR86","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1212\/WNL.43.4.662","volume":"43","author":"DW Paty","year":"1993","unstructured":"Paty DW, Li DKB (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 43(4):662","journal-title":"Neurology"},{"key":"545_CR87","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"issue":"7","key":"545_CR88","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/1352458511398887","volume":"17","author":"S Ragheb","year":"2011","unstructured":"Ragheb S, Li Y, Simon KM, VanHaerents S, Galimberti D, De Riz M, Fenoglio C, Scarpini E, Lisak R (2011) Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler J 17(7):819\u2013829","journal-title":"Mult Scler J"},{"issue":"3","key":"545_CR89","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.brainresrev.2004.06.006","volume":"46","author":"G Raivich","year":"2004","unstructured":"Raivich G, Banati R (2004) Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Brain Res Rev 46(3):261\u2013281. https:\/\/doi.org\/10.1016\/j.brainresrev.2004.06.006","journal-title":"Brain Res Brain Res Rev"},{"key":"545_CR90","first-page":"2262","volume":"356","author":"RM Ransahoff","year":"2007","unstructured":"Ransahoff RM (2007) Natalizumab for multiple sclerosis. N Engl J Med 356:2262\u20132269","journal-title":"N Engl J Med"},{"issue":"3","key":"545_CR91","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nrneurol.2015.14","volume":"11","author":"RM Ransohoff","year":"2015","unstructured":"Ransohoff RM, Hafler DA, Lucchinetti CF (2015) Multiple sclerosis-a quiet revolution. Nat Rev Neurol 11(3):134\u2013142. https:\/\/doi.org\/10.1038\/nrneurol.2015.14","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"545_CR92","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378(2):169\u2013180. https:\/\/doi.org\/10.1056\/NEJMra1401483","journal-title":"N Engl J Med"},{"key":"545_CR93","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, Confavreaux C, Galetta SL, Radu E-W, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911\u2013923","journal-title":"N Engl J Med"},{"key":"545_CR94","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","volume":"81","author":"N Schwab","year":"2013","unstructured":"Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Gobel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfar A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kumpfel T, Meinl I, Niessen K, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Windel H (2013) L-selection is a possible biomarker for PML risk in natalizumab-treated MS patients. Neurology 81:865\u2013871","journal-title":"Neurology"},{"issue":"8","key":"545_CR95","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1177\/1352458515607651","volume":"22","author":"N Schwab","year":"2016","unstructured":"Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Gorlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Canto E, Kumpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfar A, Montalban X, Meuth SG, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H (2016) PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler 22(8):1048\u20131060","journal-title":"Mult Scler"},{"key":"545_CR96","doi-asserted-by":"publisher","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","volume":"105","author":"TD Shenkenberg","year":"1986","unstructured":"Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105:67\u201381","journal-title":"Ann Intern Med"},{"issue":"2","key":"545_CR97","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00415-007-0730-5","volume":"255","author":"Y Shimizu","year":"2008","unstructured":"Shimizu Y, Yokoyama K, Misu T, Takahashi T, Fujihara K, Kikuchi S, Itoyama Y, Iwata M (2008) Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 255(2):305\u2013307. https:\/\/doi.org\/10.1007\/s00415-007-0730-5","journal-title":"J Neurol"},{"issue":"3","key":"545_CR98","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/WCO.000000000000563","volume":"31","author":"M Sospedra","year":"2018","unstructured":"Sospedra M (2018) B cells in multiple sclerosis. Curr Opin Neurol 31(3):256\u2013262. https:\/\/doi.org\/10.1097\/WCO.000000000000563","journal-title":"Curr Opin Neurol"},{"key":"545_CR99","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.clim.2017.06.006","volume":"181","author":"M Spadaro","year":"2017","unstructured":"Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, Bertolotto A (2017) Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients. Clin Immunol 181:83\u201388. https:\/\/doi.org\/10.1016\/j.clim.2017.06.006","journal-title":"Clin Immunol"},{"issue":"2","key":"545_CR100","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56(2):185\u2013196. https:\/\/doi.org\/10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"545_CR101","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/eji.1830010406","volume":"1","author":"D Teitelbaum","year":"1971","unstructured":"Teitelbaum D, Meshhorer A, Hirshfeld T, Arnon R, Sela M (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1:242\u2013248","journal-title":"Eur J Immunol"},{"issue":"10130","key":"545_CR102","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/s0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (2018) Multiple sclerosis. Lancet 391(10130):1622\u20131636. https:\/\/doi.org\/10.1016\/s0140-6736(18)30481-1","journal-title":"Lancet"},{"issue":"5","key":"545_CR103","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ane.13147","volume":"140","author":"A Tolf","year":"2019","unstructured":"Tolf A, Fagius J, Carlson K, Akerfeldt T, Granberg T, Larsson EM, Burman J (2019) Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation. Acta Neurol Scand 140(5):320\u2013327. https:\/\/doi.org\/10.1111\/ane.13147","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"545_CR104","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","volume":"266","author":"R Topakian","year":"2019","unstructured":"Topakian R, Zimprich F, Iglseder S, Embacher N, Guger M, Stieglbauer K, Langenscheidt D, Rath J, Quasthoff S, Simschitz P, Wanschitz J, Windisch D, Muller P, Oel D, Schustereder G, Einsiedler S, Eggers C, Loscher W (2019) High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol 266(3):699\u2013706","journal-title":"J Neurol"},{"key":"545_CR105","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","volume":"31","author":"BD Trapp","year":"2008","unstructured":"Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247\u2013269. https:\/\/doi.org\/10.1146\/annurev.neuro.30.051606.094313","journal-title":"Annu Rev Neurosci"},{"issue":"2","key":"545_CR106","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","volume":"86","author":"O Tuohy","year":"2015","unstructured":"Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, May K, Button T, Azzopardi L, Kousin-Ezewu O, Fahey MT, Jones J, Compston DA, Coles A (2015) Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 86(2):208\u2013215. https:\/\/doi.org\/10.1136\/jnnp-2014-307721","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"545_CR107","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13063-019-3346-z","volume":"20","author":"A Uccelli","year":"2019","unstructured":"Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS, MESEMS Study Group (2019) MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I\/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials 20(1):263. https:\/\/doi.org\/10.1186\/s13063-019-3346-z","journal-title":"Trials"},{"key":"545_CR108","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FGA Van der Meche","year":"1992","unstructured":"Van der Meche FGA, Schmitz PIM, The Dutch Guillain-Barre Study Group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 326:1123\u20131129","journal-title":"N Engl J Med"},{"key":"545_CR109","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","volume":"60","author":"DMW Wingerchuk","year":"2003","unstructured":"Wingerchuk DMW, Weinshenker BG (2003) Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 60:848\u2013853","journal-title":"Neurology"},{"key":"545_CR110","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1474-","volume":"9","author":"D Wynn","year":"2010","unstructured":"Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O\u2019Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW (2010) Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 9:381\u2013390. https:\/\/doi.org\/10.1016\/S1474-","journal-title":"Lancet Neurol"},{"issue":"8","key":"545_CR111","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1084\/jem.20132477","volume":"211","author":"R Yamasaki","year":"2014","unstructured":"Yamasaki R, Lu H, Butovsky O, Ohno N, Rietsch AM, Cialic R, Wu PM, Doykan CE, Lin J, Cotleur AC, Kidd G, Zorlu MM, Sun N, Hu W, Liu L, Lee J-C, Taylor SE, Uehlein L, Dixon D, Gu J, Floruta CM, Zhu M, Charo IF, Weiner HL, Ransohoff RM (2014) Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med 211(8):1533\u20131549. https:\/\/doi.org\/10.1084\/jem.20132477","journal-title":"J Exp Med"},{"issue":"1\u20132","key":"545_CR112","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","volume":"227","author":"B Yamout","year":"2010","unstructured":"Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, Mahfouz R, Khalil-Hamdan R, Kreidieh NM, El-Sabban M, Bazarbachi A (2010) Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol 227(1\u20132):185\u2013189. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.07.013","journal-title":"J Neuroimmunol"},{"issue":"5","key":"545_CR113","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1182\/blood-2005-04-1496","volume":"106","author":"E Zappia","year":"2005","unstructured":"Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106(5):1755\u20131761. https:\/\/doi.org\/10.1182\/blood-2005-04-1496","journal-title":"Blood"},{"issue":"1\u20132","key":"545_CR114","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jneuroim.2011.06.006","volume":"237","author":"Z Zhang","year":"2011","unstructured":"Zhang Z, Zhang ZY, Schittenhelm J, Wu Y, Meyermann R, Schluesener HJ (2011) Parenchymal accumulation of CD163+ macrophages\/microglia in multiple sclerosis brains. J Neuroimmunol 237(1\u20132):73\u201379. https:\/\/doi.org\/10.1016\/j.jneuroim.2011.06.006","journal-title":"J Neuroimmunol"},{"issue":"7","key":"545_CR115","doi-asserted-by":"publisher","first-page":"e1700369","DOI":"10.1002\/ardp.201700369","volume":"351","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Zhang D, Liu Y, Yang D, Ran F, Wang ML, Zhao G (2018) Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: preclinical and clinical developments of small molecule inhibitors. Arch Pharm (Weinheim) 351(7):e1700369. https:\/\/doi.org\/10.1002\/ardp.201700369","journal-title":"Arch Pharm (Weinheim)"}],"container-title":["Handbook of Experimental Pharmacology","Pharmacology of Immunosuppression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2021_545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T04:00:21Z","timestamp":1675742421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2021_545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783031051173","9783031051180"],"references-count":115,"URL":"https:\/\/doi.org\/10.1007\/164_2021_545","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"1 October 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}